These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 26516201)
1. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Vacchelli E; Ma Y; Baracco EE; Sistigu A; Enot DP; Pietrocola F; Yang H; Adjemian S; Chaba K; Semeraro M; Signore M; De Ninno A; Lucarini V; Peschiaroli F; Businaro L; Gerardino A; Manic G; Ulas T; Günther P; Schultze JL; Kepp O; Stoll G; Lefebvre C; Mulot C; Castoldi F; Rusakiewicz S; Ladoire S; Apetoh L; Bravo-San Pedro JM; Lucattelli M; Delarasse C; Boige V; Ducreux M; Delaloge S; Borg C; André F; Schiavoni G; Vitale I; Laurent-Puig P; Mattei F; Zitvogel L; Kroemer G Science; 2015 Nov; 350(6263):972-8. PubMed ID: 26516201 [TBL] [Abstract][Full Text] [Related]
2. A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. Le Naour J; Liu P; Zhao L; Adjemian S; Sztupinszki Z; Taieb J; Mulot C; Silvin A; Dutertre CA; Ginhoux F; Sauvat A; Cerrato G; Castoldi F; Martins I; Stoll G; Paillet J; Mangane K; Richter C; Kepp O; Maiuri MC; Pietrocola F; Vandenabeele P; André F; Delaloge S; Szallasi Z; Laurent-Puig P; Zucman-Rossi J; Zitvogel L; Pol JG; Vacchelli E; Kroemer G Cancer Discov; 2021 Feb; 11(2):408-423. PubMed ID: 33046534 [TBL] [Abstract][Full Text] [Related]
3. Getting Tumor Dendritic Cells to Engage the Dead. Cucolo L; Minn AJ Cancer Cell; 2015 Dec; 28(6):685-687. PubMed ID: 26678335 [TBL] [Abstract][Full Text] [Related]
5. Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. Vacchelli E; Enot DP; Pietrocola F; Zitvogel L; Kroemer G Cancer Res; 2016 Jun; 76(11):3122-6. PubMed ID: 27197163 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. Baracco EE; Pietrocola F; Buqué A; Bloy N; Senovilla L; Zitvogel L; Vacchelli E; Kroemer G Oncoimmunology; 2016 Jun; 5(6):e1139275. PubMed ID: 27471610 [TBL] [Abstract][Full Text] [Related]
7. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Apetoh L; Tesniere A; Ghiringhelli F; Kroemer G; Zitvogel L Cancer Res; 2008 Jun; 68(11):4026-30. PubMed ID: 18519658 [TBL] [Abstract][Full Text] [Related]
8. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753 [TBL] [Abstract][Full Text] [Related]
10. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Ma Y; Mattarollo SR; Adjemian S; Yang H; Aymeric L; Hannani D; Portela Catani JP; Duret H; Teng MW; Kepp O; Wang Y; Sistigu A; Schultze JL; Stoll G; Galluzzi L; Zitvogel L; Smyth MJ; Kroemer G Cancer Res; 2014 Jan; 74(2):436-45. PubMed ID: 24302580 [TBL] [Abstract][Full Text] [Related]
11. Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Hannani D; Locher C; Yamazaki T; Colin-Minard V; Vetizou M; Aymeric L; Viaud S; Sanchez D; Smyth MJ; Bruhns P; Kroemer G; Zitvogel L Cell Death Differ; 2014 Jan; 21(1):50-8. PubMed ID: 23744294 [TBL] [Abstract][Full Text] [Related]
12. Annexin A1 is associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway. Cheng TY; Wu MS; Lin JT; Lin MT; Shun CT; Huang HY; Hua KT; Kuo ML Cancer; 2012 Dec; 118(23):5757-67. PubMed ID: 22736399 [TBL] [Abstract][Full Text] [Related]
13. No impact of cancer and plague-relevant Petrazzuolo A; Le Naour J; Vacchelli E; Gaussem P; Ellouze S; Jourdi G; Solary E; Fontenay M; Smadja DM; Kroemer G Oncoimmunology; 2020 Dec; 9(1):1857112. PubMed ID: 33344044 [TBL] [Abstract][Full Text] [Related]
14. STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. Yang H; Yamazaki T; Pietrocola F; Zhou H; Zitvogel L; Ma Y; Kroemer G Cancer Res; 2015 Sep; 75(18):3812-22. PubMed ID: 26208907 [TBL] [Abstract][Full Text] [Related]
15. Assessment of annexin A1 release during immunogenic cell death. Baracco EE; Petrazzuolo A; Kroemer G Methods Enzymol; 2019; 629():71-79. PubMed ID: 31727257 [TBL] [Abstract][Full Text] [Related]
16. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy. Salem ML Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701 [TBL] [Abstract][Full Text] [Related]
17. Formyl Peptide receptor 1 expression is associated with tumor progression and survival in gastric cancer. Cheng TY; Wu MS; Lin JT; Lin MT; Shun CT; Hua KT; Kuo ML Anticancer Res; 2014 May; 34(5):2223-9. PubMed ID: 24778024 [TBL] [Abstract][Full Text] [Related]
18. Annexin 1 released by necrotic human glioblastoma cells stimulates tumor cell growth through the formyl peptide receptor 1. Yang Y; Liu Y; Yao X; Ping Y; Jiang T; Liu Q; Xu S; Huang J; Mou H; Gong W; Chen K; Bian X; Wang JM Am J Pathol; 2011 Sep; 179(3):1504-12. PubMed ID: 21782780 [TBL] [Abstract][Full Text] [Related]
19. Human formyl peptide receptor 1 (FPR1) c.32C>T SNP is associated with decreased soluble E-selectin levels. Benachour H; Zaiou M; Herbeth B; Lambert D; Lamont JV; Pfister M; Siest G; Tiret L; Blankenberg S; Fitzgerald PS; Visvikis-Siest S Pharmacogenomics; 2009 Jun; 10(6):951-9. PubMed ID: 19530962 [TBL] [Abstract][Full Text] [Related]
20. An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1). Chiang SF; Huang KC; Chen WT; Chen TW; Ke TW; Chao KSC Oncoimmunology; 2021 May; 10(1):1926074. PubMed ID: 34026338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]